Timber Pharmaceuticals' Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer® (TMB-002) in EuropeGlobeNewsWire • 03/17/21
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital IchthyosisGlobeNewsWire • 03/15/21
Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences ConferenceGlobeNewsWire • 03/05/21
Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical OfficerGlobeNewsWire • 01/25/21
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic SclerosisGlobeNewsWire • 01/12/21
Timber Pharmaceuticals to Present at the 13th Annual LD Micro Main Event ConferenceGlobeNewsWire • 12/08/20
